Truist Financial Issues Positive Forecast for ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price

ANI Pharmaceuticals (NASDAQ:ANIP) had its price target increased by Truist Financial from $62.00 to $65.00 in a research report sent to investors on Monday,Benzinga reports. Truist Financial currently has a hold rating on the specialty pharmaceutical company’s stock.

Other analysts have also issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 17th. JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price for the company. Guggenheim reaffirmed a “buy” rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, April 11th. Jefferies Financial Group began coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a “buy” rating and a $80.00 price objective for the company. Finally, StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, April 16th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $80.13.

ANI Pharmaceuticals Stock Down 1.7 %

Shares of NASDAQ:ANIP opened at $68.00 on Monday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a market cap of $1.48 billion, a P/E ratio of -123.64 and a beta of 0.49. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $70.48. The company’s 50-day moving average price is $63.43 and its two-hundred day moving average price is $59.53.

Insiders Place Their Bets

In related news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares of the company’s stock, valued at approximately $4,048,711.50. The trade was a 1.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Meredith Cook sold 400 shares of the stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $68.96, for a total value of $27,584.00. Following the transaction, the vice president now owns 80,145 shares of the company’s stock, valued at approximately $5,526,799.20. This trade represents a 0.50 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,200 shares of company stock worth $197,792. Corporate insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC boosted its position in ANI Pharmaceuticals by 89.3% during the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company’s stock worth $55,437,000 after acquiring an additional 473,097 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of ANI Pharmaceuticals by 4.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company’s stock worth $37,906,000 after purchasing an additional 30,420 shares in the last quarter. Deep Track Capital LP boosted its holdings in ANI Pharmaceuticals by 28.6% during the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company’s stock worth $35,879,000 after purchasing an additional 144,214 shares during the last quarter. Global Alpha Capital Management Ltd. grew its position in ANI Pharmaceuticals by 16.4% in the fourth quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company’s stock valued at $34,525,000 after purchasing an additional 88,100 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in ANI Pharmaceuticals by 159.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after buying an additional 340,854 shares during the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.